This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shattuck, D. L. Articles by Sweeney, C. Search for Related Content PubMed PubMed Citation Articles by Shattuck, D. L. Articles by Sweeney, C.

Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells

University of California Davis Cancer Center, Sacramento, California

Requests for reprints: Colleen Sweeney, University of California Davis Cancer Center, Research Building III, Room 1400C, 4645 2nd Avenue, Sacramento, CA 95817. Phone: 916-734-0726; Fax: 916-734-0190; E-mail: casweeney{at}ucdavis.edu.

Key Words: Trastuzumab resistance • Her2 • Met receptor

Her2 is overexpressed in 20% to 30% of breast tumors and correlates with reduced disease-free and overall patient survival. Trastuzumab, a humanized monoclonal antibody directed against Her2, represents the first Her2-targeted therapy, which decreases the risk of relapse and prolongs patient survival. Resistance to trastuzumab, both inherent and treatment-acquired, represents a significant barrier to the effective treatment of Her2 (+) breast cancer. The Met receptor tyrosine kinase is aberrantly expressed in breast cancer and predicts poor patient prognosis. In this study, we find that Met is frequently expressed in Her2-overexpressing breast cancer cells, as well as Her2 (+) breast cancer. Importantly, Met contributes to trastuzumab resistance, as inhibition of Met sensitizes cells to trastuzumab-mediated growth inhibition, whereas Met activation protects cells against trastuzumab by abrogating p27 induction. Remarkably, Her2-overexpressing breast cancer cells rapidly up-regulate Met expression after trastuzumab treatment, promoting their own resistance. Our study suggests that a subset of Her2 (+) patients may benefit from combined inhibition of Her2 and Met. [Cancer Res 2008;68(5):1471–7]

This article has been cited by other articles:

				X. Huang, L. Gao, S. Wang, J. L. McManaman, A. D. Thor, X. Yang, F. J. Esteva, and B. Liu Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin Cancer Res., February 1, 2010; 70(3): 1204 - 1214. [Abstract] [Full Text] [PDF]

				P. R. Pohlmann, I. A. Mayer, and R. Mernaugh Resistance to Trastuzumab in Breast Cancer Clin. Cancer Res., December 15, 2009; 15(24): 7479 - 7491. [Abstract] [Full Text] [PDF]

				D. Lesniak, Y. Xu, J. Deschenes, R. Lai, J. Thoms, D. Murray, S. Gosh, J. R. Mackey, S. Sabri, and B. Abdulkarim {beta}1-Integrin Circumvents the Antiproliferative Effects of Trastuzumab in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer Cancer Res., November 15, 2009; 69(22): 8620 - 8628. [Abstract] [Full Text] [PDF]

				M. Narayan, J. A. Wilken, L. N. Harris, A. T. Baron, K. D. Kimbler, and N. J. Maihle Trastuzumab-Induced HER Reprogramming in "Resistant" Breast Carcinoma Cells Cancer Res., March 15, 2009; 69(6): 2191 - 2194. [Abstract] [Full Text] [PDF]

				L. Toschi and P. A. Janne Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer Clin. Cancer Res., October 1, 2008; 14(19): 5941 - 5946. [Abstract] [Full Text] [PDF]